Latest From Complexa Inc.
Finance Watch: Pfizer Ventures' Dalton Makes Sense Of Neuroscience Focus Within New $600m VC Fund Commitment
Venture Capital Edition: Pfizer deprioritized neuroscience as an early R&D focus earlier this year, but will stay involved by spending 25% of the $600m added to its venture fund on neurology investments. Also, China VC investment keeps up fast pace and Alta Partners closes a new $130m health care fund.
This week’s announcements include the retirement of GlaxoSmithKline’s CFO, new CEOs at Complexa, Synlogic and Horizon Discovery, and other new hires at TP Therapeutics and Motif Bio, and a new board member at DBV Technologies.
Edmond De Rothschild Investment Partners unveils the largest life science and medical device venture fund to be raised in Europe. Olivier Litzka tells Scrip that the continent can now boast a public market machinery that contributes to potentially lucrative exits for investors.
Complexa topped the list of recent venture capital financings with a $62m Series C round, followed by Evelo and Kezar with $50m Series B rounds and LogicBio with a $45m Series B.
- Therapeutic Areas
- Metabolic Disorders
- Renal System
- North America
- Parent & Subsidiaries
- Complexa Inc.
- Senior Management
Francisco D Salva, Pres. & CEO
Federica O'Brien, CFO
Diane Jorkasky, MD, Head, Dev. & CMO
Theodore (Theo) Danoff, MD, PhD, CMO
- Contact Info
Phone: (412) 727-8727
1055 Westlakes Dr.
Berwyn, PA 19312
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.